October 18, 2016 Non Regulatory Results from InDex Pharmaceuticals’ COLLECT study well received at UEGW Read more
October 18, 2016 Non Regulatory Resultat från InDex Pharmaceuticals COLLECT-studie väl mottagna vid UEGW Read more
October 10, 2016 Non Regulatory InDex Pharmaceuticals presents results from the COLLECT study at the United European Gastroenterology Week 2016 Read more
October 10, 2016 Non Regulatory InDex Pharmaceuticals presenterar resultat från COLLECT-studien vid United European Gastroenterology Week 2016 Read more
September 30, 2016 Non Regulatory InDex Pharmaceuticals announces the outcome of its initial public offering in connection with planned listing on Nasdaq First North Stockholm Read more
September 30, 2016 Non Regulatory InDex Pharmaceuticals offentliggör utfall i nyemission av aktier i samband med planerad listning på Nasdaq First North Stockholm Read more
September 26, 2016 Non Regulatory InDex Pharmaceuticals ends the subscription period for the initial public offering in connection with listing on Nasdaq First North Tuesday, September 27 Read more
September 26, 2016 Non Regulatory InDex Pharmaceuticals avslutar teckningsperiod för nyemission inför notering på Nasdaq First North tisdag 27 september Read more
September 14, 2016 Non Regulatory InDex Pharmaceuticals initiates the subscription period for the initial public offering in connection with planned listing on Nasdaq First North Read more
September 14, 2016 Non Regulatory InDex Pharmaceuticals inleder teckningsperiod för nyemission inför notering på Nasdaq First North Read more
September 13, 2016 Non Regulatory InDex Pharmaceuticals offentliggör prospekt avseende nyemission i samband med planerad listning på Nasdaq First North Stockholm Read more
September 13, 2016 Non Regulatory InDex Pharmaceuticals publishes prospectus regarding initial public offering in connection with planned listing on Nasdaq First North Stockholm Read more
September 13, 2016 Non Regulatory InDex Pharmaceuticals genomför nyemission i samband med planerad listning på Nasdaq First North Stockholm Read more
September 13, 2016 Non Regulatory InDex Pharmaceuticals conducts initial public offering in connection with planned listing on Nasdaq First North Stockholm Read more
August 25, 2016 Non Regulatory InDex Pharmaceuticals Holding AB – Delårsrapport 27 juni – 30 juni 2016 Read more
August 25, 2016 Non Regulatory InDex Pharmaceuticals Holding AB – Interim Report 27 June – 30 June 2016 Read more
August 15, 2016 Non Regulatory InDex Pharmaceuticals AB – Delårsrapport januari – juni 2016 Read more
August 15, 2016 Non Regulatory InDex Pharmaceuticals AB – Interim Report January – June 2016 Read more
July 13, 2016 Non Regulatory InDex Pharmaceuticals publicerar resultat från COLLECT-studien Read more
May 23, 2016 Non Regulatory InDex Pharmaceuticals receives grant from Sweden´s innovation agency Vinnova for pre-clinical development of DIMS compounds in inflammation Read more
May 23, 2016 Non Regulatory InDex Pharmaceuticals får finansiering från Vinnova för preklinisk utveckling av DIMS-substanser mot inflammatoriska sjukdomar Read more
March 7, 2016 Non Regulatory InDex Pharmaceuticals Receives FDA Clearance of IND for Cobitolimod (Kappaproct®) Phase IIb Trial Read more
March 7, 2016 Non Regulatory InDex Pharmaceuticals erhåller FDA-godkännande av IND för fas IIb-studie med cobitolimod (Kappaproct®) Read more
February 10, 2016 Non Regulatory InDex Pharmaceuticals receives approval of the International Nonproprietary Name (INN) cobitolimod for their lead drug candidate Kappaproct® Read more
February 10, 2016 Non Regulatory InDex Pharmaceuticals erhåller godkännande av det internationella generiska namnet (INN) cobitolimod för sin ledande läkemedelskandidat Kappaproct® Read more